Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Stopping tyrosine kinase inhibitors (TKIs) treatment is an emerging goal of chronic myeloid leukemia (CML) management. Several studies have demonstrated the feasibility of stopping treatment. A sustained molecular response on long-term TKIs therapy seems to be necessary prior to attempting treatment-free remission (TFR). However, there were none available characteristics or indicators which can predict the outcome of TKIs discontinuation now. In our opinion, factors which could reflex the progression probability of minimal residual leukemia such as leukemia stem cells and microenvironment might play a pivotal role. Besides, novel methods for further monitoring would also attract much attention of the researchers in this area.

[1]  M. Tulliez,et al.  Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. , 2017, Blood.

[2]  J. Radich,et al.  NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  U. Olsson‐Strömberg,et al.  Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia , 2016, Leukemia.

[4]  A. Guo,et al.  A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors , 2016, Oncotarget.

[5]  T. Hughes,et al.  Moving treatment-free remission into mainstream clinical practice in CML. , 2016, Blood.

[6]  Wei Liu,et al.  miR-146b-5p within BCR-ABL1-Positive Microvesicles Promotes Leukemic Transformation of Hematopoietic Cells. , 2016, Cancer research.

[7]  H. Kantarjian,et al.  Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors , 2015, Cancer.

[8]  M. Shurin,et al.  Myeloid regulatory cells in tumor spreading and metastasis. , 2015, Immunobiology.

[9]  H. Jaspan,et al.  The Role of Myeloid-Derived Suppressor Cells in Immune Ontogeny , 2014, Front. Immunol..

[10]  G. Stefanzl,et al.  Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. , 2014, Blood.

[11]  A. Guo,et al.  BCR-ABL1–positive microvesicles transform normal hematopoietic transplants through genomic instability: implications for donor cell leukemia , 2014, Leukemia.

[12]  W. M. Smit,et al.  Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). , 2013, European journal of cancer.

[13]  Ç. Gerçel-Taylor,et al.  The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids , 2013, Front. Genet..

[14]  J. Melo,et al.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.

[15]  J. Radich.  Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  P. Rousselot,et al.  Curing Chronic Myeloid Leukemia , 2012, Current Hematologic Malignancy Reports.

[17]  A. Bennaceur-Griscelli,et al.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.

[18]  Hamid Cheshmi.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[19]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[20]  K. Rezvani,et al.  Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. , 2010, Blood.

[21]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.